Cough treatment – facts, myths, and new perspective at known drugs Review article
Article Sidebar
Published:
Sep 10, 2024
Keywords:
cough, cough treatment, mucokinetic drugs, antitussive drugs
Main Article Content
Abstract
Cough is one of the most common symptoms of respiratory diseases. Acute, subacute and chronic coughs are distinguished. Mucokinetic drugs are widely used in patients with dry cough, difficulty in expectorating sputum. Antitussive drugs are used in the case of a persistent cough that worsens the quality of life, during acute infections, exacerbation of chronic diseases, and in the case of treatment-resistant cough. Bromhexidine and ambroxol are well-known mucokinetic drugs that facilitate expectoration of retained secretions. Central antitussive drugs are characterized by high effectiveness, but also many side effects. For this reason, it is worth using peripheral medications with a confirmed safety profile.
Article Details
How to Cite
Białek-Gosk, K. (2024). Cough treatment – facts, myths, and new perspective at known drugs. Medycyna Faktow (J EBM), 17(2(63), 295-300. https://doi.org/10.24292/01.MF.0224.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. An Am Thor Soc. 2014; 11: 404-406.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Irwin RS, Baumann MH, Bolser DC et al. Diagnosis and management of cough. ACCP evidenced-based clinical practice guidelines. Chest. 2006; 129(suppl): 1s-23s.
4. Witek TJ, Ramsey DL, Carr AN et al. The natural history of community-acquired common colds symptoms assessed over 4-years. Rhinology. 2015; 53(1): 81-8.
5. Hryniewicz W, Albrecht P, Radzikowski A. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Program Ochrony Antybiotyków. Narodowy Instytut Leków, Warszawa 2016.
6. Krenke R, Chorostowska-Wynimko J, Dąbrowska M et al. Postępowanie w kaszlu u osób dorosłych – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2018; 6(4): 425-52.
7. Parker SM, Smith JA, Birring SS et al. British Thoracic Society Clinical Statement on chronic cough in adults. Thorax. 2023; 78(6): 3-19.
8. Medycyna Praktyczna.
9. Olivieri D, Ciaccia A, Marangio E et al. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration. 1991; 58(3-4): 117-21.
10. Wilkinson M, Sugumar K, Milan SJ et al. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews. 2014; 5.
11. Crockett A, Cranston JM, Alpers JH et al. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews. 2001; 1.
12. Aihara M, Dobashi K, Akiyama M et al. Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages Respiration. 2000; 67(6): 662-71.
13. Nowak D. Antioxidative features of ambroxol usefulness in COPD Review Pneumonol Alergol Pol. 2001; 69(9-10): 590-3.
14. Jahnz-Różyk K, Kucharczyk A, Chciałowski A et al. The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients. Pol Merkur Lekarski. 2001; 11(63): 239-43.
15. Schulz M, Hammerlein A, Hinkel U et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther. 2006; 44(9): 409-21.
16. Morice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. BTS Guidelines. Thorax. 2006; 61(suppl I): i1-i24.
17. Irwin RS, Baumann MH, Bolser DC et al. Diagnosis and management of cough. ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(suppl): 1s-23s.
18. Morice AH, Millqvist E, Bieksiene K et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020; 55(1).
19. Zanasi A, Lanata L, Fontana G et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015; 10(1): 19.
20. Lee SP, Lee SM, Lee BJ et al. Effectiveness and Safety of Codeine and Levodropropizine in Patients With Chronic Cough Randomized Controlled Trial J Korean Med Sci. 2022; 37(36): e275.
21. Bruschi C, Crotto P, Dacosto E et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Clinical Trial Pulm Pharmacol Ther. 2003; 16(4): 231-6.
22. Lejeune J, Weibel MA. Comparison of 2 antitussive agents in pediatrics (butamirate citrate in drinkable solution and zipeprol syrup. Rev Med Suisse Romande. 1990; 110: 181-5.
23. Germouty J, Weibel MA. Clinical comparison of butamirate citrate with a codeine-based antitussive agent. Rev Med Suisse Romande. 1990; 110: 983-6.
24. Charpin J, Weibel MA. Comparative evaluation of the antitussive activity of butamirate citrate linctus versus clobutinol syrup. Respiration. 1990; 57: 275-9.
25. Faruqi S, Wright C, Thompson R et al. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers. Br J Clin Pharmacol. 2014; 78:6: 1272-1280.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Irwin RS, Baumann MH, Bolser DC et al. Diagnosis and management of cough. ACCP evidenced-based clinical practice guidelines. Chest. 2006; 129(suppl): 1s-23s.
4. Witek TJ, Ramsey DL, Carr AN et al. The natural history of community-acquired common colds symptoms assessed over 4-years. Rhinology. 2015; 53(1): 81-8.
5. Hryniewicz W, Albrecht P, Radzikowski A. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Program Ochrony Antybiotyków. Narodowy Instytut Leków, Warszawa 2016.
6. Krenke R, Chorostowska-Wynimko J, Dąbrowska M et al. Postępowanie w kaszlu u osób dorosłych – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2018; 6(4): 425-52.
7. Parker SM, Smith JA, Birring SS et al. British Thoracic Society Clinical Statement on chronic cough in adults. Thorax. 2023; 78(6): 3-19.
8. Medycyna Praktyczna.
9. Olivieri D, Ciaccia A, Marangio E et al. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration. 1991; 58(3-4): 117-21.
10. Wilkinson M, Sugumar K, Milan SJ et al. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews. 2014; 5.
11. Crockett A, Cranston JM, Alpers JH et al. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews. 2001; 1.
12. Aihara M, Dobashi K, Akiyama M et al. Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages Respiration. 2000; 67(6): 662-71.
13. Nowak D. Antioxidative features of ambroxol usefulness in COPD Review Pneumonol Alergol Pol. 2001; 69(9-10): 590-3.
14. Jahnz-Różyk K, Kucharczyk A, Chciałowski A et al. The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients. Pol Merkur Lekarski. 2001; 11(63): 239-43.
15. Schulz M, Hammerlein A, Hinkel U et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther. 2006; 44(9): 409-21.
16. Morice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. BTS Guidelines. Thorax. 2006; 61(suppl I): i1-i24.
17. Irwin RS, Baumann MH, Bolser DC et al. Diagnosis and management of cough. ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(suppl): 1s-23s.
18. Morice AH, Millqvist E, Bieksiene K et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020; 55(1).
19. Zanasi A, Lanata L, Fontana G et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015; 10(1): 19.
20. Lee SP, Lee SM, Lee BJ et al. Effectiveness and Safety of Codeine and Levodropropizine in Patients With Chronic Cough Randomized Controlled Trial J Korean Med Sci. 2022; 37(36): e275.
21. Bruschi C, Crotto P, Dacosto E et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Clinical Trial Pulm Pharmacol Ther. 2003; 16(4): 231-6.
22. Lejeune J, Weibel MA. Comparison of 2 antitussive agents in pediatrics (butamirate citrate in drinkable solution and zipeprol syrup. Rev Med Suisse Romande. 1990; 110: 181-5.
23. Germouty J, Weibel MA. Clinical comparison of butamirate citrate with a codeine-based antitussive agent. Rev Med Suisse Romande. 1990; 110: 983-6.
24. Charpin J, Weibel MA. Comparative evaluation of the antitussive activity of butamirate citrate linctus versus clobutinol syrup. Respiration. 1990; 57: 275-9.
25. Faruqi S, Wright C, Thompson R et al. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers. Br J Clin Pharmacol. 2014; 78:6: 1272-1280.